AgingResearch.NewsJoin free

Nuvig Therapeutics

CompanyUnited States

Nuvig Therapeutics develops one asset, in phase 2 (NVG-2089 in chronic inflammatory demyelinating polyneuropathy). Mostly protein or enzyme; based in the United States.

1
Asset
Furthest stage
Phase 2
Raised
US$161m
1
Trial
0
Signals

Pipeline

1

  • NVG-2089

    Phase 2, Protein or enzyme, chronic inflammatory demyelinating polyneuropathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Funding rounds and grants1
  • Similar companies1

Intelligence